非小细胞肺癌分子靶向药物治疗的研究进展

非小细胞肺癌(NSCLC)为最常见的肺癌病理类型,约占肺癌总数的 85%。大多数肺癌患者在确诊时已属晚期,失去手术机会, 保守治疗成为其重要治疗手段,但晚期肺癌患者的预后仍不理想。近年来,分子靶向治疗在肿瘤治疗领域取得重要进展,亦有研究显示 其在 NSCLC 的临床实践中发挥显著疗效。除表皮生长因子受体(EGFR)和间变淋巴瘤激酶(ALK)等主要基因突变之外,血管内皮生 长因子(VEGF)、ROS1、c-MET、RET、K-RAS、BRAF 也是目前 NSCLC 分子靶向治疗的相关靶点。综述 NSCLC 分子靶向药物治疗 的研究进展,旨在为该疾病的治疗提供参考。

The Latest Advance in Molecular Targeted Therapy for Non-small Cell Lung Cancer

Non-small cell lung cancer(NSCLC) is the most common pathological type of lung cancer, which accounts for about 85% of cases. Unfortunately, most patients do not have the chance to do surgery because diagnosis is always con rmed at late stage. Although conservative treatment is available as an important measure, the prognosis of advanced NSCLC patients is still unsatisfactory. In recent years, molecular targeted therapies have achieved great progress in tumor therapy and played an essential role in the clinical treatment of NSCLC. In addition to epidermal growth factor receptor(EGFR) and anaplastic lymphoma kinase(ALK), other targets involved in the targeted therapies for NSCLC include vascular endothelial growth factor(VEGF), ROS1, MET, RET, K-RAS and BRAF. The paper reviewed the advance in molecular targeted therapy for NSCLC, so as to provide reference for its treatment.